In a significant development, Medicare is set to cover GLP-1 weight loss drugs like Wegovy and Zepbound for seniors, beginning July 1. This landmark change will allow eligible older Americans to access these obesity treatments for only $50 a month. While many seniors may be unaware of this new coverage, programs are being launched to facilitate access and guide them through eligibility requirements. Pharmacies like Walgreens and Walmart are additionally expanding their services to aid Medicare patients in navigating this newly available support. However, there are complexities in the rollout, and some beneficiaries, such as those under TRICARE for Life, may find themselves excluded. As this initiative proceeds, stakeholders are analyzing the implications for healthcare infrastructure and pharmaceutical access.